Main navigation

For US Healthcare Professionals Only

Important Safety Information
Prescribing Information
Patient Site
Request Samples For US Healthcare Professionals Only

Request Samples

About EPI
- About EPI in Patients Without CF
- About EPI in Patients With CF
Efficacy
MOA
Safety
Dosing
- Dosing in Patients Without CF
- Dosing in Patients With CF
FAQs
Coverage and Support
- Non-CF Coverage and Support
- CF Coverage and Support

About EPI
- About EPI in Patients Without CF
- About EPI in Patients With CF
Efficacy
MOA
Safety
Dosing
- Dosing in Patients Without CF
- Dosing in Patients With CF
FAQs
Coverage and Support
- Non-CF Coverage and Support
- CF Coverage and Support

About EPI

Living with EPI can be challenging¹

Learn about EPI in
PATIENTS WITHOUT CF

Learn about EPI in
PATIENTS WITH CF

Not actual patients. CF=cystic fibrosis; EPI=exocrine pancreatic insufficiency.

Reference: 1. Othman MO, Harb D, Barkin JA. Introduction and practical approach to exocrine pancreatic insufficiency for the practicing clinician. Int J Clin Pract. 2018;72(2):e13066. doi:10.1111/ijcp.13066

IMPORTANT SAFETY INFORMATION
AND INDICATIONS

IMPORTANT SAFETY INFORMATION

Warnings and Precautions

Fibrosing Colonopathy

Fibrosing colonopathy is a rare serious adverse reaction associated with high-dose use of pancreatic enzyme replacement.
Exercise caution when doses of ZENPEP exceed 2,500 lipase units/kg of body weight per meal (or greater than 10,000 lipase units/kg of body weight per day).

INDICATIONS AND USAGE

ZENPEP® (pancrelipase) is a combination of porcine-derived lipases, proteases, and amylases indicated for the treatment of exocrine pancreatic insufficiency due to cystic fibrosis, or other conditions.

Potential for Irritation to Oral Mucosa

To avoid irritation of oral mucosa, care should be taken to ensure the ZENPEP capsule or its contents are not crushed, chewed, or retained in the mouth. ZENPEP may be added to a small amount of acidic soft food.

Potential for Risk of Hyperuricemia

Exercise caution when prescribing ZENPEP to patients with gout, renal impairment or hyperuricemia.

Potential Viral Exposure from the Product Source

There is theoretical risk of viral transmission with all pancreatic enzyme products, including ZENPEP; however, no cases of transmission of an infectious illness associated with the use of porcine pancreatic extracts have been reported.

Allergic Reactions

Rarely, severe allergic reactions including anaphylaxis, asthma, hives, and pruritus have been reported with other pancreatic enzyme products with different formulations of the same active ingredient (pancrelipase).
Exercise caution when administering pancrelipase to a patient with a known allergy to proteins of porcine origin.

Adverse Reactions

The most common adverse events (≥6% of patients treated with ZENPEP) were abdominal pain, flatulence, headache, cough, decreased weight, early satiety, and contusion.

Additional Important Safety Information

ZENPEP is not interchangeable with any other pancrelipase product.
Dosing should not exceed the recommended maximum dosage set forth by the Cystic Fibrosis Foundation Consensus Conferences Guidelines.

Please see the full Prescribing Information for ZENPEP.

All trademarks are owned by Société des Produits Nestlé S.A.,
Vevey, Switzerland. ©2023 Nestlé.
ZP-PM-USA-0081 12/22

The product information provided in this site is intended for
residents of the United States.

Full Prescribing Information
Patient Medication Guide
Privacy Policy
Terms of Use

Contact Us
Privacy Notice (USA)
Terms & Conditions
Sitemap

Please verify that you are a US Healthcare Professional.
This site is intended for US Healthcare Professionals.

I AM A US-LICENSED HEALTHCARE
PROFESSIONAL

I AM NOT A US-LICENSED HEALTHCARE PROFESSIONAL